vs
Side-by-side financial comparison of Entrada Therapeutics, Inc. (TRDA) and Zeo Energy Corp. (ZEO). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $18.6M, roughly 1.1× Zeo Energy Corp.). Zeo Energy Corp. runs the higher net margin — -10.8% vs -84.4%, a 73.6% gap on every dollar of revenue. On growth, Zeo Energy Corp. posted the faster year-over-year revenue change (-0.4% vs -65.2%). Zeo Energy Corp. produced more free cash flow last quarter ($2.3M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -4.0%).
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
TRDA vs ZEO — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.6M | $18.6M |
| Net Profit | $-17.3M | $-2.0M |
| Gross Margin | — | — |
| Operating Margin | -106.0% | -11.8% |
| Net Margin | -84.4% | -10.8% |
| Revenue YoY | -65.2% | -0.4% |
| Net Profit YoY | -173.8% | -360.9% |
| EPS (diluted) | $-0.42 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.6M | ||
| Q3 25 | — | $23.9M | ||
| Q2 25 | — | $18.1M | ||
| Q1 25 | $20.6M | $8.8M | ||
| Q4 24 | $37.4M | $18.6M | ||
| Q3 24 | $19.6M | $19.7M | ||
| Q2 24 | $94.7M | $14.8M | ||
| Q1 24 | $59.1M | $20.1M |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-3.2M | ||
| Q2 25 | — | $-2.4M | ||
| Q1 25 | $-17.3M | $-6.4M | ||
| Q4 24 | $1.1M | $-435.3K | ||
| Q3 24 | $-14.0M | $-424.3K | ||
| Q2 24 | $55.0M | $-277.8K | ||
| Q1 24 | $23.5M | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 57.9% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 99.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 50.2% | ||
| Q2 24 | — | 52.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | -11.8% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | — | -15.8% | ||
| Q1 25 | -106.0% | -153.8% | ||
| Q4 24 | -15.7% | -6.0% | ||
| Q3 24 | -110.7% | -15.2% | ||
| Q2 24 | 56.4% | -18.0% | ||
| Q1 24 | 35.7% | -20.1% |
| Q4 25 | — | -10.8% | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | — | -13.3% | ||
| Q1 25 | -84.4% | -72.4% | ||
| Q4 24 | 3.0% | -2.3% | ||
| Q3 24 | -71.7% | -2.2% | ||
| Q2 24 | 58.1% | -1.9% | ||
| Q1 24 | 39.7% | -7.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-0.42 | $-0.48 | ||
| Q4 24 | $-0.20 | $1.11 | ||
| Q3 24 | $-0.35 | $-0.08 | ||
| Q2 24 | $1.55 | $0.03 | ||
| Q1 24 | $0.68 | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $67.8M | $6.1M |
| Total DebtLower is stronger | — | $79.1K |
| Stockholders' EquityBook value | $417.3M | $5.3M |
| Total Assets | $486.5M | $56.9M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $3.9M | ||
| Q2 25 | — | $68.7K | ||
| Q1 25 | $67.8M | $2.9M | ||
| Q4 24 | $101.2M | $5.6M | ||
| Q3 24 | $78.0M | $4.3M | ||
| Q2 24 | $185.3M | $5.3M | ||
| Q1 24 | $68.4M | — |
| Q4 25 | — | $79.1K | ||
| Q3 25 | — | $84.6K | ||
| Q2 25 | — | $642.8K | ||
| Q1 25 | — | $715.4K | ||
| Q4 24 | — | $787.7K | ||
| Q3 24 | — | $858.6K | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | — | $748.8K |
| Q4 25 | — | $5.3M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | — | $-59.4M | ||
| Q1 25 | $417.3M | $-23.1M | ||
| Q4 24 | $428.7M | $-88.9M | ||
| Q3 24 | $422.4M | $-39.3M | ||
| Q2 24 | $429.9M | $-53.0M | ||
| Q1 24 | $269.4M | $-173.0M |
| Q4 25 | — | $56.9M | ||
| Q3 25 | — | $58.5M | ||
| Q2 25 | — | $46.2M | ||
| Q1 25 | $486.5M | $47.4M | ||
| Q4 24 | $526.3M | $61.0M | ||
| Q3 24 | $554.6M | $47.1M | ||
| Q2 24 | $582.0M | $49.1M | ||
| Q1 24 | $510.8M | $50.1M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.5M | $2.4M |
| Free Cash FlowOCF − Capex | $-39.7M | $2.3M |
| FCF MarginFCF / Revenue | -192.9% | 12.2% |
| Capex IntensityCapex / Revenue | 5.6% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-58.0M | $-9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $-6.6M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | $-38.5M | $-2.3M | ||
| Q4 24 | $-31.6M | $3.5M | ||
| Q3 24 | $-24.3M | $162.2K | ||
| Q2 24 | $39.8M | $-2.2M | ||
| Q1 24 | $-25.5M | $-10.2M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-6.8M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | $-39.7M | $-2.6M | ||
| Q4 24 | $-32.2M | $3.4M | ||
| Q3 24 | $-24.9M | $116.5K | ||
| Q2 24 | $38.8M | $-2.3M | ||
| Q1 24 | $-26.4M | $-10.4M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -15.0% | ||
| Q1 25 | -192.9% | -30.0% | ||
| Q4 24 | -86.2% | 18.2% | ||
| Q3 24 | -127.3% | 0.6% | ||
| Q2 24 | 41.0% | -15.6% | ||
| Q1 24 | -44.6% | -51.5% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | 5.6% | 4.2% | ||
| Q4 24 | 1.7% | 0.5% | ||
| Q3 24 | 3.3% | 0.2% | ||
| Q2 24 | 1.1% | 0.7% | ||
| Q1 24 | 1.4% | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -27.94× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.72× | — | ||
| Q1 24 | -1.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TRDA
Segment breakdown not available.
ZEO
| Nonrelated Party | $18.1M | 98% |
| Related Party | $432.1K | 2% |
